Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Illumina (ILMN)

Illumina to buy SomaLogic and proteomics assets from Standard BioTools for $350 million

Neutral Impact 4 of 5 m&a Written later

Illumina agreed on June 22, 2025 to acquire SomaLogic and related proteomics assets from Standard BioTools for $350 million in cash at closing, plus up to $75 million in milestone payments and royalties. The deal adds an aptamer-based proteomics platform to Illumina's portfolio and is expected to close in the first half of 2026, subject to regulatory clearance.

Key points

  • Cash payment of $350 million at closing, subject to customary adjustments, plus up to $75 million in milestone payments and royalties
  • Closing expected in the first half of 2026, subject to Hart-Scott-Rodino clearance and other conditions
  • Termination fee of $14.5 million payable by Illumina in certain regulatory failure scenarios; outside date March 23, 2026

The filing

CompanyIllumina (ILMN)
Form8-K, current report
Filed with the SECJun 23, 2025, 9:24 AM ET
Accession number0001193125-25-144290

Items reported: 1.01 Material Definitive Agreement8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 23, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.